Metastatic Hepatocellular Carcinoma Clinical Trials

11 recruiting

Metastatic Hepatocellular Carcinoma Trials at a Glance

13 actively recruiting trials for metastatic hepatocellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Pittsburgh, New York, and Jacksonville. Lead sponsors running metastatic hepatocellular carcinoma studies include National Cancer Institute (NCI), BeOne Medicines, and Alnylam Pharmaceuticals.

Browse metastatic hepatocellular carcinoma trials by phase

Treatments under study

About Metastatic Hepatocellular Carcinoma Clinical Trials

Looking for clinical trials for Metastatic Hepatocellular Carcinoma? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Hepatocellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH104 enrolled2 locationsNCT07219459
Recruiting
Phase 1Phase 2

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled11 locationsNCT07227012
Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled20 locationsNCT06427941
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
National Cancer Institute (NCI)92 enrolled4 locationsNCT06811116
Recruiting
Phase 1

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaHepatocellular Cancer
National Cancer Institute (NCI)38 enrolled1 locationNCT05003895
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
Emory University39 enrolled4 locationsNCT07174570
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Not Applicable

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Metastatic Gastroesophageal Junction AdenocarcinomaMetastatic Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v8+41 more
University of California, San Francisco28 enrolled2 locationsNCT04221893
Recruiting
Phase 2

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Locally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8+6 more
Academic and Community Cancer Research United122 enrolled16 locationsNCT05168163
Recruiting

Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma

Locally Advanced Hepatocellular CarcinomaLiver CirrhosisNon-metastatic Hepatocellular Carcinoma
Universitair Ziekenhuis Brussel100 enrolled1 locationNCT06873269